SEC Form 4 · accession 0001623919-16-000101
EndoChoice Holdings, Inc. · GI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David L Kaufman
Director
Period of report
Nov 22, 2016
Accepted (ET)
Nov 23, 2016 · 10:22 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001623919
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, par value $0.001 per share | Jun 9, 2016 | W | 1,500 | $0.00 | A | 12,587 | D | |
| Common stock, par value $0.001 per shareF1 | Nov 22, 2016 | D | 12,587 | $8.00 | D | 0 | D | |
| Common stock, par value $0.001 per shareF1,F2 | Nov 22, 2016 | D | 2,088,209 | $8.00 | D | 0 | I | By Envest III, LLC |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reporting Person disposed of shares of Issuer Common Stock pursuant to a cash tender offer made by Boston Scientific Corporation as more fully described in the Schedule 14D-9 filed by Issuer with the Securities and Exchange Commission on October 7, 2016, and subsequent amendments thereto (the "Merger"). The Issuer's Board of Directors approved in advance the dispositions by the Reporting Person in the tender offer.
- F2The reporting person is a Founder and Senior Managing Director of Envest Holdings LLC and as a result may be deemed to beneficially own the shares owned by Envest Holdings or related entities.